Navigation Links
Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference
Date:8/11/2011

MONMOUTH JUNCTION, N.J., Aug. 11, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President and CEO of Insmed, will be presenting a corporate overview at the 2011 Wedbush Securities Life Sciences Management Access Conference on Tuesday, August 16, 2011, at 8:00 AM ET, in New York.

A live audio webcast will be available on the Investors page of Insmed's website, http://www.insmed.com.  The webcast will also be archived for 90 days.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, and has a proprietary protein platform aimed at niche markets with high unmet medical need. Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases.  For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to our financial position, results of operations, the status and the results of preclinical studies and clinical trials and preclinical and clinical data described herein, the timing of responses to information and data requests from FDA, the development of our products, and the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  Our results may be affected by s
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Andrea Drucker Joins Insmed as General Counsel
2. Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication
3. Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
4. Insmed to Host Second Quarter 2009 Conference Call
5. Insmed Announces Addition to the Russell 3000(R) Index
6. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
7. Insmed CEO Resigns Due to Health Concerns
8. Insmed Announces First Quarter 2009 Financial Results
9. Insmed Regains NASDAQ Compliance
10. Insmed to Host First Quarter 2009 Conference Call
11. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
(Date:2/27/2015)... Feb. 27, 2015 Research and Markets ( ... Market Report of Trypsin" report to their offering. ... aims at providing comprehensive data on Trypsin globally and regionally ... North America , Latin America ... attention to Trypsin This report focuses on three ...
(Date:2/27/2015)... 2015 The fully automated supercritical ... can sequentially analyze up to 48 samples utilizing ... detection of targets by mass spectrometry. , ... the measurement requirements of a wide range of ... delivery and search for disease biomarkers, additives in ...
(Date:2/27/2015)... DIEGO , Feb. 27, 2015  Pfenex Inc. ... the development of biosimilar therapeutics, today announced that it ... Francisco Marriott Marquis on March 2 nd at ... participate on a panel discussing the current state of ... of Biosimilars . For more information ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Global Market Report of Trypsin 2014-2018 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
... GRINSTEAD, West Sussex, U.K. and CLEVELAND, Nov. 18 ... and premier provider of diagnostic systems and susceptibility ... Grinstead, U.K., manufacturing and research and development facility ... product line for susceptibility and identification testing. The ...
... ... characterizing DNA-protein interactions. , ... Madison, WI, USA (PRWEB) November 18, 2009 -- Promega Corporation ... a study using the HaloCHIP™ System and high-throughput promoter assays demonstrate the ability ...
... , , MONROVIA, Calif. ... Corp . ("Niusule" or the "Company") (OTC Bulletin Board: ... selling nutritional products for children, today announced that the Company,s ... largest city in China. The Company has entered into a ...
Cached Biology Technology:TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 2TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 3TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 4Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity 2Niusule Expands Geographic Footprint in China 2Niusule Expands Geographic Footprint in China 3
(Date:1/22/2015)... Fla. , Jan. 13, 2015  Today, FreeWavz ... technology, launched its crowdfunding campaign on Fundable, ... the build of production capacity to meet customer ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... (NASDAQ: NXTD and NXTDW) a biometric authentication company focused ... the Wocket™ smart wallet at CES 2015 in Las Vegas ... of the "11 Hot Products at CES" in a review published in ... by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... ability of Australian desert birds to adapt to cycles ... a new book launched today by CSIRO Publishing at ... and Bust: Bird stories for a dry country sheds ... ecological change. Studies of key bird species, such ...
... advantage in the media. A new study by Dr. ... the journal of Israel,s National Security College, describes how ... too. "Information warfare" plays a crucial ... so than conventional weapons. Therefore, the information warfare against ...
... the natural glue that marine mussels use to stick to ... of researchers led by North Carolina State University has devised ... traditional sutures and result in less scarring, faster recovery times ... Traditionally, there have been two ways to join tissue ...
Cached Biology News:Fly like a bird through boom and bust 2Information warfare in the 21st century: Ideas are sometimes stronger than bombs 2Shellfish and inkjet printers may hold key to faster healing from surgeries 2
... Protein Phosphatase-2A (PPase-2A) is a serine/threonine ... It is isolated as the heterodimer of ... has the ability to dephosphorylate the a-subunit ... subunit, PPase-2A has broad substrate specificity and ...
... is a high performance spectral scanning ... incubator. With the advanced SkanIt Software ... for drug discovery assay development. Varioskan ... intensity, time-resolved fluorescence and photometric assays ...
... wide variety of solvent vapors that can contaminate and ... allows for the collection of liquid into a self ... waiting period., Ultra low -104 o C ... , Digital Display of temperature ...
Immulon 2HB, Flat Bottom, 50/Bx; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
Biology Products: